周一盘中，美股上市公司脑再生科技（RGC）股价大幅上涨410.83%，创下历史新高，引发市场广泛关注。该公司专注于研发治疗神经认知障碍的中药，尤其是针对注意力缺陷多动障碍（ADHD）和自闭症谱系障碍（ASD）。
脑再生科技股价飙升可能与多个因素有关。首先，该公司被视为脑机接口概念股，而这一领域近期受到了极大关注。今年3月，中国国家医保局为脑机接口技术单独立项，设立了相关价格项目。此外，6月初埃隆·马斯克旗下的脑机接口公司Neuralink完成了6.5亿美元的融资，估值达到90亿美元，进一步推高了市场对这一领域的期待。
然而，值得注意的是，脑再生科技目前尚未实现盈利，且面临着持续经营的不确定性。公司2021至2024财年的营收均为0，且在2024财年财报中明确表示"可能永远无法盈利"。此外，公司股票流通性较低，截至2024年6月底，公司仅有11.2%的股份在市场流通，这种低流通性可能加剧了股价的波动。投资者在关注该股票时应当谨慎，充分评估相关风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.